Literature DB >> 30190195

Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.

Lawrence Paszat1, Rinku Sutradhar2, Limei Zhou3, Sharon Nofech-Mozes4, Eileen Rakovitch5.   

Abstract

INTRODUCTION: Individual prediction of local recurrence (LR) risk after breast-conserving surgery (BCS) for ductal carcinoma-in-situ (DCIS) is needed to identify women at low risk, for whom radiotherapy may be omitted. PATIENTS AND
METHODS: Three predictive models of LR-clinicopathologic factors (CPF) alone; CPF + estrogen receptor (ER) + human epidermal growth factor receptor 2 (HER2); and CPF + DCIS score (DS)-were developed among 1102 cases of DCIS in patients with complete covariate and outcome data. Categorizations of discrete variables and transformations of continuous variables were examined in Cox models; 2-way interactions and interactions with time were assessed. Internal validation was performed by bootstrapping. Individual predicted 10-year LR risks were computed from covariate values, estimated regression parameters, and estimated baseline survival function. Accuracy was assessed by c statistics and calibration plots.
RESULTS: The strongest prediction model incorporated CPF + DS. The c statistics for CPF + DS, CPF + ER + HER2, or CPF-alone models were 0.7025, 0.6879, and 0.6825, respectively. The CPF + DS model was better calibrated at predicting low (≤ 10%) individual 10-year LR risks after BCS alone than those incorporating CPF + ER + HER2 or CPF alone, evidenced by c statistics and plots of observed by predicted risks. Among women aged ≥ 50 with no adverse CPF, the CPF + DS model identified the greatest proportion of women (62.3%) with predicted individual 10-year LR ≤ 10% without radiotherapy compared to the CPF + ER + HER2 (50.9%) or CPF alone (46.5%) models.
CONCLUSION: Individual prediction of LR incorporating DS is more accurate and identifies a higher proportion of women with low predicted risk of LR after BCS alone, for whom radiotherapy may be omitted.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ductal carcinoma in situ; Local recurrence; Multigene expression assay; Prediction model; Radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 30190195     DOI: 10.1016/j.clbc.2018.07.018

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  5 in total

1.  DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.

Authors:  Eileen Rakovitch; Sameer Parpia; Anne Koch; Laval Grimard; Hany Soliman; Christiaan Stevens; Francisco Perera; Iwa Kong; Senti Senthelal; Margaret Anthes; Ericka Wiebe; Jeffrey Cao; Mira Goldberg; Sally Smith; Luciana Spadafora; Timothy J Whelan
Journal:  Breast Cancer Res Treat       Date:  2021-04-08       Impact factor: 4.872

Review 2.  Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review.

Authors:  Renée S J M Schmitz; Erica A Wilthagen; Frederieke van Duijnhoven; Marja van Oirsouw; Ellen Verschuur; Thomas Lynch; Rinaa S Punglia; E Shelley Hwang; Jelle Wesseling; Marjanka K Schmidt; Eveline M A Bleiker; Ellen G Engelhardt
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

3.  Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.

Authors:  Jean L Wright; Habib Rahbar; Samilia Obeng-Gyasi; Ruth Carlos; Judy Tjoe; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2021-11-23       Impact factor: 50.717

4.  Overdetection of Breast Cancer.

Authors:  Martin J Yaffe; James G Mainprize
Journal:  Curr Oncol       Date:  2022-05-30       Impact factor: 3.109

5.  MiRNA expression deregulation correlates with the Oncotype DX® DCIS score.

Authors:  Olivier Loudig; Megan I Mitchell; Iddo Z Ben-Dov; Christina Liu; Susan Fineberg
Journal:  Breast Cancer Res       Date:  2022-09-12       Impact factor: 8.408

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.